Melanotan 1 (MT-1) in Australia: A Research Reference

Melanotan 1 in Australia: the short answer

Melanotan 1, also written Melanotan I or MT-1, is a synthetic linear peptide and an analogue of alpha-melanocyte-stimulating hormone. It is the melanocortin analogue also known as afamelanotide, or NDP-MSH, and it is studied in pigmentation and photoprotection research. In Australia it is not TGA-approved for human use and is supplied by NovaPeptides strictly for laboratory and research use only. For a research buyer the two things that matter most are an accurate account of its regulatory status and a verifiable Certificate of Analysis for the exact batch received.

This page is a reference for research audiences. It explains what Melanotan 1 is, the melanocortin receptors it is investigated against, the research areas where it appears, how afamelanotide fits the picture, and what buying from a transparent Australian-owned supplier looks like. It contains no dosing guidance and makes no therapeutic claims.

What is Melanotan 1 (MT-1)?

Melanotan 1 is a synthetic analogue of alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH, one of the body's naturally occurring melanocortin peptides. Structurally it is a linear peptide, most precisely described as [Nle4, D-Phe7]-alpha-MSH, a sequence often abbreviated to NDP-MSH. Two substitutions in the native sequence make the molecule considerably more stable and more active at its target receptor than alpha-MSH itself, which is why it became a widely cited tool compound in melanocortin research.

As a research chemical, Melanotan 1 is characterised by its amino acid sequence, its molecular weight, and its purity profile. In a laboratory context these are the properties a Certificate of Analysis is expected to document, so that the material used in any study is identified and quantified rather than assumed. This is also what separates MT-1 from its better-known relative Melanotan 2, which is a distinct cyclic peptide with a different receptor profile.

Mechanism and receptor targets

In preclinical research, Melanotan 1 is described as a potent agonist at the melanocortin 1 receptor, or MC1R, the receptor that sits on melanocytes and is central to pigmentation biology. Compared with the broadly non-selective Melanotan 2, MT-1 is generally characterised in the literature as more selective for MC1R, which is one reason it is used when researchers want to probe that receptor in particular.

When MC1R is activated in these models, downstream signalling through the cyclic AMP pathway has been studied in relation to the synthesis of eumelanin, the darker form of melanin. Because eumelanin is the pigment most associated with absorbing and dissipating ultraviolet light, MC1R signalling is a common entry point for photoprotection research in cell and animal models. The wider melanocortin family also includes MC3R, MC4R and MC5R, and MT-1 is often set against MT-2 precisely because their receptor selectivity profiles differ.

• Studied as a linear analogue of the natural melanocortin peptide alpha-MSH.
• Characterised as a potent agonist at the melanocortin 1 receptor (MC1R).
• Generally described as more MC1R-selective than the cyclic Melanotan 2.
• MC1R activation studied via cyclic AMP signalling and eumelanin synthesis.
• Used as a reference or probe compound in receptor selectivity studies.

What Melanotan 1 is studied for

The Melanotan 1 research literature clusters around two closely linked themes. The first is pigmentation biology, where MT-1 is used to probe how MC1R signalling relates to melanin synthesis in melanocyte and animal models. The second is photoprotection, the study of how greater eumelanin content relates to a cell or tissue's response to ultraviolet light. Both of these describe areas of investigation, not outcomes promised to any person.

Because Melanotan 1 is the same molecule as afamelanotide, it also sits at the centre of the melanocortin agonist literature more broadly. Researchers use it as a well-characterised MC1R reference point when studying the melanocortin system, receptor pharmacology and pigment cell biology. In every case the correct framing is that the compound has been researched in models, not that it produces any effect in a reader.

The research landscape and afamelanotide

Melanotan 1 occupies an unusual position, because the molecule itself, under the name afamelanotide, has been through formal clinical development. Afamelanotide is regulated as a prescription medicine in the jurisdictions where it is approved, delivered there as a controlled subcutaneous implant for a rare inherited light-sensitivity condition, erythropoietic protoporphyria. That is a regulatory and scientific fact about the molecule, and it is a large part of why MT-1 appears so often in the melanocortin research record.

It is important not to collapse those two things together. The clinical product afamelanotide is a finished, regulated medicine prepared and administered under medical supervision. The Melanotan 1 supplied by NovaPeptides is a research chemical for laboratory use only. It is not that medicine, and it is not TGA-approved for human use. The practical distinction between MT-1 and its relative MT-2 is set out below.

• Melanotan 1 (MT-1, afamelanotide, NDP-MSH): linear alpha-MSH analogue, more MC1R-selective, supplied for research use only.
• Melanotan 2 (MT-2): cyclic peptide, broad non-selective melanocortin agonist, also supplied for research use only.
• Afamelanotide as a medicine: the same molecule as MT-1, clinically developed and prescription-regulated where approved, and distinct from any research chemical.
• Native alpha-MSH: the naturally occurring melanocortin peptide both Melanotan analogues are modelled on.

How Melanotan 1 is handled in a laboratory context

In a research setting, Melanotan 1 is treated like any other lyophilised peptide research chemical. It typically arrives as a freeze-dried powder that is kept cold and away from light until it is prepared for an experiment, then reconstituted with an appropriate solvent in line with the study protocol. Correct labelling, cold storage and batch records are all part of ordinary laboratory practice with a compound of this kind.

None of this is administration guidance, and nothing here describes doses. It simply reflects that a research chemical belongs in a research environment, handled by people equipped to work with peptides and to keep the records that make results traceable. NovaPeptides publishes general handling and storage references for laboratory audiences, and the Certificate of Analysis for each batch is what anchors those records to the exact material in hand.

• Supplied as a lyophilised (freeze-dried) powder for laboratory preparation.
• Kept cold and protected from light, consistent with peptide handling practice.
• Prepared only within a defined research protocol, never as personal guidance.
• Logged against its batch reference and Certificate of Analysis for traceability.

Sourcing and reading a Melanotan 1 COA

A Certificate of Analysis is the single most useful document when sourcing Melanotan 1 in Australia. A meaningful MT-1 COA identifies the compound, reports its purity, and ties the result to a specific batch rather than to the product line in general. The NovaPeptides approach is an independent Novagen Certificate of Analysis on every batch, each carrying a unique key so the certificate can be checked against the material actually received.

When a COA is reviewed, the details that matter are the analytical method used to establish identity and purity, the batch or lot reference that matches the vial, and a way to confirm the certificate is genuine. A verifiable key removes the guesswork, which is why NovaPeptides has issued them on research peptide batches for Australians across more than three years of supply.

• Compound identity stated clearly as Melanotan 1 (MT-1).
• A purity figure supported by a named analytical method.
• A batch or lot reference that matches the vial received.
• A unique key that lets the certificate be verified independently.

Why researchers source MT-1 from NovaPeptides

For research buyers in Australia, sourcing transparency is the deciding factor with a compound like Melanotan 1. NovaPeptides is Australian owned and Gold Coast based, and has supplied research peptides to Australians for over three years. That track record matters, because it means the certificates, the verification process and the logistics have all been used in practice rather than promised on a listing.

Every NovaPeptides batch ships with an independent Novagen Certificate of Analysis carrying a unique verifiable key, so identity and purity can be confirmed rather than assumed. Orders are sent with discreet tracked shipping, and Gold Coast orders are eligible for same-day dispatch, so research material reaches a laboratory quickly and with a clear chain of delivery. Everything is supplied strictly for laboratory and research use only.

Research use only: status and responsibility

Melanotan 1 is supplied by NovaPeptides strictly for laboratory and research use only. It is not TGA-approved for human use, it has not been evaluated by the Therapeutic Goods Administration for safety, quality or efficacy in people, and nothing on this page should be read as encouragement to use it outside a research context or as guidance of any kind. The clinical medicine afamelanotide is a separate, regulated product and is not what is offered here.

The reassurance NovaPeptides offers is grounded in what is true and verifiable: Australian ownership, a Gold Coast base, an independent Novagen Certificate of Analysis with a unique key on every batch, discreet tracked shipping, same-day Gold Coast dispatch, and a record of supplying research peptides to Australians for over three years. Those are the facts a research buyer can check, and they are the basis on which Melanotan 1 is offered.

Frequently asked questions

Related guides